Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
12 papers
Recent·Most cited
A. Sakoguchi, S. G. Chamberlain, A. M. Morch, T. E. Harrison, M. L. Dustin, H. Arase, M. K. Higgins, S. Iwanaga
The paper identifies RIFINs that bind both inhibitory and activating KIR receptors, revealing their role in modulating NK cell activation during malaria infection.
bioRxiv · Apr 30, 2024Microbiology
E. Urano, Y. Itoh, T. Suzuki, T. Sasaki, J.-i. Kishikawa, K. Akamatsu, Y. Higuchi, Y. Sakai, T. Okamura, S. Mitoma, F. Sugihara, A. Takada, M. Kimura, M. Hirose, T. Sasaki, , T. Okamoto
This paper shows an engineered ACE2 decoy neutralizes Omicron subvariants and is effective in treating SARS-CoV-2 infection in macaques.
bioRxiv · Dec 29, 2022 · PreprintMicrobiology
M. Kohyama, T. Suzuki, W. Nakai, C. Ono, S. Matsuoka, K. Iwatani, Y. Liu, Y. Sakai, A. Nakagawa, K. Tomii, K. Ohmura, M. Okada, Y. Matsuura, S. Oshima, Y. Maeda, , H. Arase
This study shows that SARS-CoV-2 ORF8 protein acts as a cytokine that promotes lung inflammation and immune dysregulation in COVID-19, suggesting it as a potential therapeutic target.
bioRxiv · Aug 1, 2022Microbiology
H. S. Ismanto, Z. Xu, D. S. Saputri, J. Wilamowski, S. Li, D. K. Nugraha, Y. Horiguchi, M. Okada, H. Arase, D. M. Standley
This study identifies infection-enhancing antibodies in COVID-19 patients and healthy donors, finding they are more frequent in patients but also present in healthy individuals.
bioRxiv · Jul 9, 2022Immunology
K. Ng, N. Faulkner, K. Finsterbusch, M. Wu, R. Harvey, S. Hussain, M. Greco, Y. Liu, S. Kjaer, C. Swanton, S. Gandhi, R. Beale, S. Gamblin, P. Cherepanov, J. Mccauley, , G. Kassiotis
This study shows that SARS-CoV-2 S2-targeted vaccination induces broad neutralizing antibodies against multiple coronaviruses and provides better protection than homologous boosting.
bioRxiv · Nov 30, 2021 · PreprintImmunology
Y. Liu, N. Arase, J.-i. Kishikawa, M. Hirose, S. Li, A. Tada, S. Matsuoka, A. Arakawa, K. Akamatsu, C. Ono, H. Jin, K. Kishida, W. Nakai, M. Kohyama, A. Nakagawa, , H. Arase
The paper shows the Delta variant can escape NTD antibodies and gain infectivity when specific RBD mutations are present, suggesting the need for updated vaccines.
bioRxiv · Aug 22, 2021 · PreprintMicrobiology
I. Kimura, Y. Kosugi, J. Wu, D. Yamasoba, E. P. Butlertanaka, Y. L. Tanaka, Y. Liu, K. Shirakawa, Y. Kazuma, R. Nomura, Y. Horisawa, K. Tokunaga, A. Takaori-Kondo, H. Arase, The Genotype to Phenotype Japan (G2P-Japan) Consortium, , K. Sato
The paper investigates the SARS-CoV-2 Lambda variant, finding it more infectious due to specific mutations and better immune evasion, contributing to its spread in South America.
bioRxiv · Jul 28, 2021Microbiology
X. Lu, Y. Hosono, S. Ishizuka, M. Nagae, E. Ishikawa, D. Motooka, Y. Ozaki, N. Sax, R. Shinnakasu, T. Inoue, T. Onodera, T. Matsumura, M. Shinkai, T. Sato, S. Nakamura, , S. Yamasaki
The paper identifies and crystallizes public TCRs from SARS-CoV-2-specific Tfh cells in COVID-19 patients, showing they recognize conserved spike epitopes and cross-react with symbiotic bacteria.
bioRxiv · Mar 23, 2021Immunology
Y. Liu, W. T. Soh, A. Tada, A. Arakawa, S. Matsuoka, E. E. Nakayama, S. Li, C. Ono, S. Torii, K. Kishida, H. Jin, W. Nakai, N. Arase, A. Nakagawa, Y. Shindo, , H. Arase
This study identifies an NTD site on SARS-CoV-2 spike protein that enhances infectivity when targeted by antibodies, and finds these antibodies are present in hospitalized patients and some uninfected donors.
bioRxiv · Dec 18, 2020Microbiology
W. T. Soh, Y. Liu, E. E. Nakayama, C. Ono, S. Torii, H. Nakagami, Y. Matsuura, T. Shioda, H. Arase
This study identifies L-SIGN and DC-SIGN as receptors for the N-terminal domain of SARS-CoV-2 spike protein, showing their role in infection and the importance of anti-NTD antibodies.
bioRxiv · Nov 5, 2020 · PreprintMicrobiology
H. Hayashi, J. Sun, Y. Yanagida, T. Otera, R. Kubota-Kotetsu, T. Shioda, C. Ono, Y. Matsuura, H. Arase, S. Yoshida, R. Nakamaru, R. Ide, A. Tenma, S. Kawabata, T. Ehara, , H. Nakagami
This study evaluates a DNA vaccine targeting SARS-CoV-2 Spike protein, showing enhanced humoral and cellular immune responses and neutralizing antibody activity.
bioRxiv · Oct 21, 2020Immunology
S. Yoshida, C. Ono, H. Hayashi, S. Shiraishi, T. Kazunori, H. Arase, Y. Matsuura, H. Nakagami
This study analyzes B cell epitopes and neutralizing activity in COVID-19 patients to identify potential vaccine targets.
bioRxiv · Jul 22, 2020Immunology